Astal Laboratories Ltd
ASTALLTDAstal Laboratories Ltd
ASTALLTD
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
HighStrong financials and growth story over the years
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 17.52 | 3.55 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.23 | 6.64 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Astal Laboratories Ltd is engaged in the pharmaceutical bulk drug business, owning a manufacturing plant for pharmaceutical intermediates in Karnataka.
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Mankind Pharma Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.31 | 0.31 | 0.30 | 0.30 | 0.20 | 0.20 | 0.21 | 3.61 | 23.66 | 47.00 | ||||||||||
Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.35 | 22.40 | 40.63 | ||||||||||
| Power & Fuel Cost | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 | |||||||||||
| Employee Cost | 0.08 | 0.09 | 0.09 | 0.07 | 0.09 | 0.06 | 0.09 | 0.06 | 0.47 | |||||||||||
| Selling & Administrative Expenses | 0.16 | 0.16 | 0.15 | 0.16 | 0.10 | 0.10 | 0.10 | 0.13 | 0.70 | |||||||||||
| Operating & Other expenses | 0.02 | 0.01 | 0.03 | 0.11 | 0.01 | 0.01 | 0.00 | 0.01 | -1.06 | |||||||||||
EBITDA | 0.03 | 0.03 | 0.01 | -0.06 | -0.02 | 0.02 | 0.00 | 0.05 | 1.13 | 6.37 | ||||||||||
| Depreciation/Amortization | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.03 | 0.07 | ||||||||||
| PBIT | 0.02 | 0.02 | 0.00 | -0.08 | -0.04 | 0.00 | -0.01 | 0.04 | 1.10 | 6.30 | ||||||||||
| Interest & Other Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.15 | ||||||||||
| PBT | 0.02 | 0.02 | 0.00 | -0.08 | -0.04 | 0.00 | -0.01 | 0.04 | 1.09 | 6.15 | ||||||||||
| Taxes & Other Items | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.02 | 0.30 | 1.42 | ||||||||||
| Net Income | 0.01 | 0.02 | 0.00 | -0.09 | -0.04 | 0.00 | -0.01 | 0.02 | 0.79 | 4.73 | ||||||||||
| EPS | 0.03 | 0.05 | 0.00 | -0.23 | -0.10 | 0.00 | -0.03 | 0.05 | 1.14 | 4.81 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Astal Laboratories Ltd | 104.92 | 3.55 | — |
| Sun Pharmaceutical Industries Ltd | 45.62 | 6.51 | 0.74% |
| Mankind Pharma Ltd | 62.83 | 12.55 | — |
| Cipla Ltd | 28.94 | 4.45 | 0.88% |
Price Comparison
Compare ASTALLTD with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Increased Total Retail Holding
In last 3 months, retail holding in the company has increased by 1.80%
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Feb 2024
Mar 2024
Jun 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
ASTALLTD has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeAstal Laboratories will hold a meeting of the Board of Directors of the Company on 27 November 2024Powered by Capital Market - Live
Net profit of Astal Laboratories rose 257.14% to Rs 2.00 crore in the quarter ended September 2024 as against Rs 0.56 crore during the previous quarter ended September 2023. Sales rose 7.43% to Rs 13.16 crore in the quarter ended September 2024 as against Rs 12.25 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales13.1612.25 7 OPM %21.964.73 - PBDT2.800.58 383 PBT2.770.56 395 NP2.000.56 257 Powered by Capital Market - Live
Astal Laboratories will hold a meeting of the Board of Directors of the Company on 12 November 2024Powered by Capital Market - Live
Net profit of Astal Laboratories rose 16800.00% to Rs 1.69 crore in the quarter ended June 2024 as against Rs 0.01 crore during the previous quarter ended June 2023. Sales rose 866.91% to Rs 13.15 crore in the quarter ended June 2024 as against Rs 1.36 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales13.151.36 867 OPM %18.100 - PBDT2.350.01 23400 PBT2.340.01 23300 NP1.690.01 16800 Powered by Capital Market - Live
Macro International reports standalone net loss of Rs 0.01 crore in the September 2021 quarter
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 139.54%, vs industry avg of 9.04%
Increasing Market Share
Over the last 5 years, market share increased from 0% to 0.01%